All In Biotech

Drug Trial Radar · NCT02059564

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Feb 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

44

Planned (sponsor's estimate)

Start

Dec 2013

Primary completion

Oct 2014

Study completion Dec 2014

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus

Conditions

  • Diabetes Mellitus

Interventions

  • HM11260CDrug

    doses of 6 mg, 16 mg

  • PlaceboDrug

    Normal saline solution

  • VictozaDrug

    doses of 1.8 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK profile of acetaminophenTime frame: 13 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanmi

    California City, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.